• 19 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Commentary
    A decade of CD4+ chimeric antigen receptor T-cell evolution in two chronic lymphocytic leukemia patients: were chronic lymphocytic leukemia cells present?
    On Feb 2, 2022, Nature published the paper titled “Decade-long leukemia remissions with the persistence of CD4+ CAR T-cells” (Nature. 2022;602:503–9. doi: 10.1038/s41586-021-04390-6). Accordin [...] Read more.
    Dimitrios Bouzianas, Stella Bouziana
    Published: October 31, 2023 Explor Target Antitumor Ther. 2023;4:1128–1135
    DOI: https://doi.org/10.37349/etat.2023.00186
    This article belongs to the special issue Novel Strategies and Targets for Immunotherapy of Cancer
    Open Access
    Perspective
    Cholesterol esterification and p53-mediated tumor suppression
    Many human cancers carry missense mutations in or deletions of the tumor protein 53 (TP53) tumor suppressor gene. TP53’s product, p53 regulates many biological processes, including cell metabolism [...] Read more.
    Youjun Li ... Edward V. Prochownik
    Published: October 31, 2023 Explor Target Antitumor Ther. 2023;4:1122–1127
    DOI: https://doi.org/10.37349/etat.2023.00185
    This article belongs to the special issue Therapeutic Targeting of the Tumor Microenvironment
    View:855
    Download:22
    Times Cited: 0
    Open Access
    Original Article
    Acryl-3,5-bis(2,4-difluorobenzylidene)-4-piperidone targeting cellular JUN proto-oncogene, AP-1 transcription factor subunit inhibits head and neck squamous cell carcinoma progression
    Aim: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with a survival rate below fifty percent. Addressing meager therapeutic options, a series of small m [...] Read more.
    Levi Arnold ... Sufi Mary Thomas
    Published: October 31, 2023 Explor Target Antitumor Ther. 2023;4:1104–1121
    DOI: https://doi.org/10.37349/etat.2023.00184
    This article belongs to the special issue Therapeutic Targeting of the Tumor Microenvironment
    View:1290
    Download:84
    Times Cited: 0
    Open Access
    Systematic Review
    Impact of coronavirus disease 2019 pandemic on good clinical practice trials in oncology
    Aim: Coronavirus disease 2019 (COVID-19) became pandemic on 11th March 2020 and it deeply stressed the healthcare system. Cancer patients represent a vulnerable population, so many recommendation [...] Read more.
    Veronica Agostinelli ... Rossana Berardi
    Published: October 30, 2023 Explor Target Antitumor Ther. 2023;4:1095–1103
    DOI: https://doi.org/10.37349/etat.2023.00183
    This article belongs to the special issue COVID-19 and Cancer
    View:645
    Download:7
    Times Cited: 0
    Open Access
    Review
    Coronavirus disease 2019 and lung cancer: where are we?
    Oncology patients are more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to hospital contact and an immunological system that can be compromised by antine [...] Read more.
    Abrahams Ocanto ... Felipe Couñago
    Published: October 30, 2023 Explor Target Antitumor Ther. 2023;4:1082–1094
    DOI: https://doi.org/10.37349/etat.2023.00182
    This article belongs to the special issue COVID-19 and Cancer
    View:768
    Download:13
    Times Cited: 0
    Open Access
    Review
    Overcoming phenotypic switching: targeting protein-protein interactions in cancer
    Alternative protein-protein interactions (PPIs) arising from mutations or post-translational modifications (PTMs), termed phenotypic switching (PS), are critical for the transmission of alternative  [...] Read more.
    Christos Ladias ... Nikolaos A. Papanikolaou
    Published: October 30, 2023 Explor Target Antitumor Ther. 2023;4:1071–1081
    DOI: https://doi.org/10.37349/etat.2023.00181
    This article belongs to the special issue Off-label drugs and -omics data in cancer treatment
    View:585
    Download:15
    Times Cited: 0
    Open Access
    Original Article
    Effect of vitamin D supplementation on inflammatory markers and total antioxidant capacity in breast cancer women using a machine learning technique
    Aim: This study aimed to establish a learning system using an artificial neural network (ANN) to predict the effects of vitamin D supplementation on the serum levels of vitamin D, inflammatory fa [...] Read more.
    Marzieh Tahmasebi ... Amir Jamshidnezhad
    Published: October 30, 2023 Explor Target Antitumor Ther. 2023;4:1059–1070
    DOI: https://doi.org/10.37349/etat.2023.00180
    View:604
    Download:13
    Times Cited: 0
    Open Access
    Systematic Review
    Effect of coronavirus disease 2019 on diagnosis and treatment of hepatocellular carcinoma: a systematic review
    Aim: Changes in strategies in the coronavirus disease 2019 (COVID-19) crisis and the imposing of restrictions have isolated many vulnerable patients including those with hepatocellular carcinoma  [...] Read more.
    Afrooz Mazidimoradi ... Hamid Salehiniya
    Published: October 26, 2023 Explor Target Antitumor Ther. 2023;4:1039–1058
    DOI: https://doi.org/10.37349/etat.2023.00179
    This article belongs to the special issue COVID-19 and Cancer
    Open Access
    Review
    Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer
    Mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) is now a drugable oncogenic driver and the KRAS G12C variant responds clinically to sotorasib and adagrasib that covalently block the cystein [...] Read more.
    Gerhard Hamilton ... Barbara Rath
    Published: October 26, 2023 Explor Target Antitumor Ther. 2023;4:1027–1038
    DOI: https://doi.org/10.37349/etat.2023.00178
    This article belongs to the special issue Integrated Approaches for Non-Small-Cell Lung Cancer
    View:899
    Download:19
    Times Cited: 0
    Open Access
    Review
    A review on in silico virtual screening methods in COVID-19 using anticancer drugs and other natural/chemical inhibitors
    The present coronavirus disease 2019 (COVID-19) pandemic scenario has posed a difficulty for cancer treatment. Even under ideal conditions, malignancies like small cell lung cancer (SCLC) are challe [...] Read more.
    Babak Sokouti
    Published: October 26, 2023 Explor Target Antitumor Ther. 2023;4:994–1026
    DOI: https://doi.org/10.37349/etat.2023.00177
    View:690
    Download:22
    Times Cited: 0